BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Terada K, Migita K, Matsushima Y, Sugimoto Y, Kamei C, Matsumoto T, Mori M, Matsunaga K, Takata J, Karube Y. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PLoS One 2018;13:e0209250. [PMID: 30557385 DOI: 10.1371/journal.pone.0209250] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Campos-peña V, Pichardo-rojas P, Sánchez-barbosa T, Ortíz-islas E, Rodríguez-pérez CE, Montes P, Ramos-palacios G, Silva-adaya D, Valencia-quintana R, Cerna-cortes JF, Toral-rios D. Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease. IJMS 2022;23:12092. [DOI: 10.3390/ijms232012092] [Reference Citation Analysis]
2 Brimson JM, Prasanth MI, Malar DS, Verma K, Plaingam W, Tencomnao T. Bacopa monnieri protects neuronal cell line and Caenorhabditis elegans models of Alzheimer’s disease through sigma-1 receptor antagonist sensitive and antioxidant pathways. NHA 2022. [DOI: 10.3233/nha-220161] [Reference Citation Analysis]
3 Turgutalp B, Bhattarai P, Ercetin T, Luise C, Reis R, Gurdal EE, Isaak A, Biriken D, Dinter E, Sipahi H, Schepmann D, Junker A, Wünsch B, Sippl W, Gulcan HO, Kizil C, Yarim M. Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer's Disease. J Med Chem 2022;65:12292-318. [PMID: 36084304 DOI: 10.1021/acs.jmedchem.2c01003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Kim HY, Lee JY, Hsieh CJ, Riad A, Izzo NJ, Catalano SM, Graham TJA, Mach RH. Screening of σ2 Receptor Ligands and In Vivo Evaluation of 11C-Labeled 6,7-Dimethoxy-2-[4-(4-methoxyphenyl)butan-2-yl]-1,2,3,4-tetrahydroisoquinoline for Potential Use as a σ2 Receptor Brain PET Tracer. J Med Chem 2022. [PMID: 35404616 DOI: 10.1021/acs.jmedchem.2c00191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Moreira NCDS, Lima JEBDF, Fiori Marchiori M, Carvalho I, Sakamoto-hojo ET. Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives. ADR 2022. [DOI: 10.3233/adr-210061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sałaciak K, Pytka K. Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders. Neurosci Biobehav Rev 2022;132:1114-36. [PMID: 34736882 DOI: 10.1016/j.neubiorev.2021.10.037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
7 Tripathi S, Mitra Mazumder P. Comprehensive investigations for a potential natural prophylaxis-A cellular and murine model for apple cider vinegar against hydrogen peroxide and scopolamine induced oxidative stress. Drug Dev Res 2021. [PMID: 34184291 DOI: 10.1002/ddr.21849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Moss DE. Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition? J Alzheimers Dis 2019;71:1099-103. [PMID: 31476160 DOI: 10.3233/JAD-190626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Ma WH, Chen AF, Xie XY, Huang YS. Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease. Neuropharmacology 2021;190:108342. [PMID: 33045243 DOI: 10.1016/j.neuropharm.2020.108342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
10 Terada K, Murata A, Toki E, Goto S, Yamakawa H, Setoguchi S, Watase D, Koga M, Takata J, Matsunaga K, Karube Y. Atypical Antipsychotic Drug Ziprasidone Protects against Rotenone-Induced Neurotoxicity: An In Vitro Study. Molecules 2020;25:E4206. [PMID: 32937854 DOI: 10.3390/molecules25184206] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Brimson JM, Brimson S, Chomchoei C, Tencomnao T. Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets 2020;24:1009-28. [PMID: 32746649 DOI: 10.1080/14728222.2020.1805435] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
12 Huang Y, Alsabbagh MW. Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review. Pharmacol Res Perspect 2020;8:e00622. [PMID: 32691984 DOI: 10.1002/prp2.622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Liu H, Zhang W, Fang Y, Yang H, Tian L, Li K, Lai W, Bian L, Lin B, Liu X, Xi Z. Neurotoxicity of aluminum oxide nanoparticles and their mechanistic role in dopaminergic neuron injury involving p53-related pathways. J Hazard Mater 2020;392:122312. [PMID: 32105957 DOI: 10.1016/j.jhazmat.2020.122312] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
14 Iimura A, Nishida E, Kusakabe M. Role of TrkA signaling during tadpole tail regeneration and early embryonic development in Xenopus laevis. Genes Cells 2020;25:86-99. [DOI: 10.1111/gtc.12740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Terada K, Migita K, Matsushima Y, Kamei C. Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders. Neural Regen Res 2019;14:1893-4. [PMID: 31290438 DOI: 10.4103/1673-5374.259609] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]